CJC-1295 without DAC FAQ: common questions answered
A peptide intended to trigger growth hormone release, with no human dosing study found.
Also called: Modified GRF 1-29, Mod GRF 1-29, Mod GRF(1-29), CJC-1295 no DAC.
GHRH analogues · Modified GHRH 1-29 analogue without an albumin-binding DAC tag.
- Is CJC-1295 without DAC FDA-approved? No approved CJC product or dose label. Withdrawal from Category 2 did not establish approval or a Category 1 compounding pathway.
- How do people take it? Under the skin, once nightly. Source: reported by users, not an established dose.
- What's the difference between CJC-1295 without DAC and Ipamorelin? CJC-1295 without DAC: a peptide intended to trigger growth hormone release, with no human dosing study found. Ipamorelin: an experimental peptide that triggers growth hormone release. Why people pair them: users combine a GHRH signal with a ghrelin signal hoping for greater GH release. No human trial tested this exact pairing.
- Can I take it with Ipamorelin? Users combine a GHRH signal with a ghrelin signal hoping for greater GH release. No human trial tested this exact pairing. No validated dose ratio or safety estimate; endocrine and glucose effects may add. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Growth hormone releasing factors, including GHRH analogues. Covers DAC and modified GRF 1-29.
- How long does a mixed vial last? Users report refrigeration. No validated mixed-vial stability or beyond-use date was found for these preparations.
Related to CJC-1295 without DAC
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
- CJC-1295 with DAC: An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- EGRIFTA WR (tesamorelin) for injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- December 4, 2024 Pharmacy Compounding Advisory Committee Meeting, FDA · 2024
- FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting December 4, 2024, US Food and Drug Administration · 2024
- Low blood sugar (hypoglycaemia), NHS · 2023
- Anticoagulant medicines - Side effects, NHS
- DailyMed - GLUCOTROL XL- glipizide tablet, extended release, Pfizer Inc. · DailyMed
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.